Epigral Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/sahagnh1zgimfkkbrcyu1qkl.pdf

Key Takeaways


Chlor-Alkali: The Margin Squeeze and the Chlorine Floor

Maulik Patel: "I think going forward, we will not see the chlorine prices in the negative zone going forward from here onwards. And that is much easier to increase the price pass on because caustic is globally decided in terms of the pricing, but the chlorine is domestic-based only."

Capex Pipeline: Commissioning, Pilots, and the FY31 Math


CPVC: Demand, Supply, and the Moat

Milind Kotecha: " So it's not that easily available. Plus, also, it takes time to get approval, then you get the volumes from the customers. So it's a gradual process. So it's not that easy. So first-mover advantages will always be there."

Specialty Transition and the Chlorotoluene Bet

Maulik Patel: " Our focus is the ortho-chlorotoluene and para-chlorotoluene, which is nobody is manufacturing in India. And we are going forward in terms of the value-added chemistry for the pharma intermediate and the agro intermediate, which can consume this chemistry right now."

Energy Strategy: Renewables Without Heavy Capex


Guidance & Commitments

CommitmentSpecificsTimeline
CPVC and ECH plant commissioningBoth plants to commission after trial runs currently underwayWithin a quarter
Hydrogen peroxide (solar grade) commissioningValue-added plant for solar application to commissionQ4 FY27
Epoxy resin plant commissioningPlant to be commissioned and drive revenueMarch 2028, revenue FY29 onward
FY31 revenue target~₹5,000–5,100 Cr at optimum utilization, based on current realizations and gradual ramp-upFY31
Renewable power share30% to35% of total power demand from solar and wind hybrid2–3 years
Chlorine price floorChlorine prices will not go into negative zone going forwardOngoing, from current quarter

Key Metrics

MetricQ2 FY27
Revenue₹752 cr, +28% YoY from ₹589 cr in Q2 FY26
Sales volume growth6% YoY
EBITDA₹136 cr, +3% YoY from ₹132 cr in Q2 FY26
EBITDA margin18%, impacted by high raw material costs from global uncertainty
PAT₹64 cr, +26% YoY from ₹51 cr in Q2 FY26
H1 FY27 revenue₹1,461 cr, +21% YoY from ₹1,204 cr in H1 FY26
H1 FY27 EBITDA margin22%
H1 FY27 PAT₹164 cr, vs ₹131 cr in H1 FY26
H1 FY27 PAT margin11%, similar to H1 FY26
ROCE15% as on 30 Sep 2026; 18% excluding capital work in progress
Net debt to EBITDA0.9x as on 30 Sep 2026, vs 0.8x as on 30 Sep 2025
Net debt₹514 cr as on 30 Sep 2026, vs ₹496 cr as on 30 Sep 2025
Capex spent in H1 FY27₹88 cr
Derivatives and specialty revenue share57% of total revenue in Q2 FY27
ECU realization₹31,000–₹32,000 in Q2 FY27; currently ₹32,000–₹33,000
Chlorine price~₹0 in Q2 FY27 and currently
CPVC realization₹120–₹125 per kg
CPVC capacity utilization60–65%
ECH capacity utilization75–80%
Hydrogen peroxide capacity utilization95%
Caustic soda capacity utilization75%
Chlorotoluene expected FY27 revenue~₹100 cr
Chlorotoluene peak revenue potential₹300–₹350 cr at optimum utilization
CPVC demand growth13% CAGR annually
Gross block~₹3,000 cr currently; expected to reach ₹3,500 cr post CPVC and ECH expansion commissioning
FY31 revenue target₹5,000–₹5,100 cr, based on current realizations and gradual ramp-up of capex
ECH captive consumption estimate~50% captively consumed once epoxy resin plant commissions, balance 50% sold in market